Alnylam Pharma Stock Price (NASDAQ:ALNY)

Add to My Stocks
$81.57 $0.56 (0.69%) ALNY stock closing price Jul 26, 2017 (Closing)
Prev Close* : $81.01
Market Cap:
Day Low: $80.49
52 Week Low: $31.38
Open: $80.84
Volume: 479318
Day High: $81.8
52 Week High: $86.92

Latest Stock Market News

Latest Articles

Alnylam Pharma News - From Partners

ALNY Stockcharts

View ALNY PE ratio, PS ratio stocks charts and compare with peers.
ALNY Chart
Note: Compare Alnylam Pharma stock price history with the index and industry peers.

Alnylam Pharma Valuation

PS ratio (
price to sales ratio
PB ratio (
price to book ratio

Alnylam Pharma Financial Ratios

Asset Turnover
Receivables Turnover
Debt to Equity

ALNY Industry Peers

Company Price Change (%)
Seattle Genetics (SGEN)55.020.51 (0.94%)
Qiagen (QGEN)34.310.12 (0.35%)
Arrowhead Pharma (ARWR)1.880.28 (17.5%)
Regulus Therapeutics (RGLS)1.190.08 (7.21%)
Benitec Biopharma (BNTC)2.340.03 (1.27%)
Sanofi (SNY)48.020.05 (0.1%)
Takeda Pharma (TKPYY)25.370 (0%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
EXACT Sciences (EXAS)39.652.32 (6.21%)
Dynavax Technologies (DVAX)10.40.5 (5.05%)
MannKind (MNKD)1.320.06 (4.76%)
BioDelivery Sciences (BDSI)3.50.15 (4.48%)
Biogen Inc (BIIB)295.6112.65 (4.47%)
Paratek Pharma (PRTK)21.450.85 (4.13%)
Vital Therapies (VTL)2.750.1 (3.77%)
Top gainers from Medical-Biomed-Genetics industry
* As of Jul 27, 2017
CompanyPriceChange (%)
Integra LifeSciences (IART)49.745.88 (10.57%)
Idera Pharma (IDRA)1.940.12 (5.83%)
Kamada (KMDA)5.150.25 (4.63%)
Peregrine Pharma (PPHM)4.30.2 (4.44%)
Fate Therapeutics (FATE)2.830.11 (3.74%)
Compugen (CGEN)3.90.15 (3.7%)
Trevena (TRVN)2.720.1 (3.55%)
Top losers from Medical-Biomed-Genetics industry
* As of Jul 27, 2017

Alnylam Pharmaceuticals, Inc. Stock News - Partner Headlines

Alnylam Pharma Financial Statements

income statement20162015201420132012
Net Sales Or Revenues47.15M41.09M50.56M47.16M66.72M
Net Income-410.1M-290.07M-360.39M-89.22M-106.01M
Total Operating Expense471.74M337.1M455.53M140.1M196.17M
view Alnylam Pharmaceuticals, Inc. income statement
balance sheet20162015201420132012
Total Assets1.26B1.39B1.08B420.53M287.52M
Total Liabilities342.58M121.79M143.32M150.18M153.46M
Shareholders Equity920.22M1.26B936.26M270.34M134.05M
view Alnylam Pharmaceuticals, Inc. balance sheet
cash flow statement20162015201420132012
Net Increase (Decrease) In Assets Liabilities17.21M35.11M-29.4M-8.11M-8.96M
Net Cash From (Used By) Operating Activities-307.7M-189.14M-165.64M-68.65M-115.6M
Increase (Decrease) In Prop Plant And Equipment-64.55M-12.95M-8.96M-4M-8.34M
view Alnylam Pharmaceuticals, Inc. cashflow statement

Alnylam Pharma Stock Message Board

Alnylam Pharma stock price ended the last trading day at 81.57. Stock price or share price can be used to find the total market value of a company. Alnylam Pharma market cap stands at 7.41B as of 26 Jul, 2017. A value investor must look at the fundamentals of a stock, and perform Alnylam Pharma valuation, even though in the short-term sentiment and current breaking news might affect Alnylam Pharma stock price.

For recognizing and analyzing the real performance of Alnylam Pharma stock, it is a standard practise to adjust historical stock prices to remove gaps caused by stock splits, dividends and distributions. 479318 shares were traded with a closing stock price of 81.57 as of 26 Jul, 2017, as can be seen from Alnylam Pharma stock quote. One can view Alnylam Pharma stock chart to follow the stock price trend. Dividends are usually paid by large stable companies, and typically not by those which are in their rapid growth stages. A company's continuing success is indicated by a steadily increasing dividend payout. One can observe stock price trends and check for volatility by checking Alnylam Pharma stock price history.